These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups. Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY. Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910 [Abstract] [Full Text] [Related]
3. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers. Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ. Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259 [Abstract] [Full Text] [Related]
8. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features. Zare SY, Lin L, Alghamdi AG, Daehne S, Roma AA, Hasteh F, Dell'Aquila M, Fadare O. Hum Pathol; 2019 Jan; 83():7-13. PubMed ID: 30121371 [Abstract] [Full Text] [Related]
9. Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory. Gulbahce HE. Am J Clin Pathol; 2017 Oct 01; 148(4):308-313. PubMed ID: 28967951 [Abstract] [Full Text] [Related]
10. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment. Polónia A, Leitão D, Schmitt F. Virchows Arch; 2016 Apr 01; 468(4):417-23. PubMed ID: 26754674 [Abstract] [Full Text] [Related]
14. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers]. Xu Y, Bai QM, Yang F, Zhu XL, Lu YM, Zhang J, Yang WT, Zhou XY. Zhonghua Bing Li Xue Za Zhi; 2016 Aug 08; 45(8):545-9. PubMed ID: 27510780 [Abstract] [Full Text] [Related]
17. Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort. Zare S, Rong J, Daehne S, Roma A, Hasteh F, Dell'Aquila M, Fadare O. Mod Pathol; 2019 Nov 08; 32(11):1566-1573. PubMed ID: 31190000 [Abstract] [Full Text] [Related]
18. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers. Tchrakian N, Flanagan L, Harford J, Gannon JM, Quinn CM. Virchows Arch; 2016 Feb 08; 468(2):207-11. PubMed ID: 26521061 [Abstract] [Full Text] [Related]